Peng Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peng Xiao has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Aina Liu
Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China
1 shared publication Boxin Chen
Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China
1 shared publicationChen Jia
Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China
1 shared publicationJia Sun
Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China
1 shared publication- Lixin Jiang
Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
1 shared publication - Mi Jian
Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
1 shared publication
Latest Publications
- Open Access
- 19 August 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (11)
Interpretable machine learning for predicting immunotherapy response in gastric cancer via serum cytokine profiling and organoid co-culture platforms
Background Immunotherapy has become a promising strategy for gastric cancer, yet predicting treatment response remains challenging. We developed an exploratory, biologically informed machine learning framework integrating peri-treatment serum biomarkers and clinical variables, with candidate cytokines informed by an in vitro patient-derived organoids (PDOs)–cancer-associated fibroblasts (CAFs)–T cells co-culture platform, to assess pathological response to PD-1 inhibitor (PD-1i)-based therapy in gastric cancer. Methods Data from 125 patients receiving PD-1i were analyzed. Serum samples collected before and after immunotherapy were tested for cytokines. Eighteen successfully established PDOs-CAFs-T cells co-culture models were used for cytokine profiling and to identify seven candidate cytokines. These cytokines were subsequently measured in paired serum samples from the 125-patient clinical cohort and combined with clinicopathological variables for machine learning model development. Tumor Regression Grade (TRG) served as the binary outcome variable, representing patients with good versus poor/no tumor regression. Experimental and clinical data were used to train predictive models with multiple algorithms, including CatBoost and several other machine learning methods. Model performance was assessed by tenfold cross-validation, ROC, precision-recall (PR) Curve, and decision curve analyses. Feature importance was interpreted using Shapley additive explanations (SHAP) and visualized using decision tree. Results The PDOs-CAFs-T cells co-culture platform showed cytokine-change trends that were generally concordant with those observed in patient serum after treatment. 10 key predictors were identified, including pre-/post-treatment maximum diameter, ycT/ycN stages, and pre- or post-treatment cytokines (IFN-α2, IL-2, IL-6, IL-8, MCP-1). In the internal testing set, the tuned CatBoost model achieved an AUC of 0.845. SHAP analysis revealed post-treatment maximum diameter and cytokine profiles as the most influential features. Decision trees clearly and interpretably present the model. Conclusion This study presents an exploratory, biologically informed machine learning framework for peri-treatment assessment of pathological response in gastric cancer. The PDOs-CAFs-T cells co-culture platform provided biological context for candidate cytokine selection.
- 19 August 2026
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (11)
Open AccessInterpretable machine learning for predicting immunotherapy response in gastric cancer via serum cytokine profiling and organoid co-culture platforms
Background Immunotherapy has become a promising strategy for gastric cancer, yet predicting treatment response remains challenging. We developed an exploratory, biologically informed machine learning framework integrating peri-treatment serum biomarkers and clinical variables, with candidate cytokines informed by an in vitro patient-derived organoids (PDOs)–cancer-associated fibroblasts (CAFs)–T cells co-culture platform, to assess pathological response to PD-1 inhibitor (PD-1i)-based therapy in gastric cancer. Methods Data from 125 patients receiving PD-1i were analyzed. Serum samples collected before and after immunotherapy were tested for cytokines. Eighteen successfully established PDOs-CAFs-T cells co-culture models were used for cytokine profiling and to identify seven candidate cytokines. These cytokines were subsequently measured in paired serum samples from the 125-patient clinical cohort and combined with clinicopathological variables for machine learning model development. Tumor Regression Grade (TRG) served as the binary outcome variable, representing patients with good versus poor/no tumor regression. Experimental and clinical data were used to train predictive models with multiple algorithms, including CatBoost and several other machine learning methods. Model performance was assessed by tenfold cross-validation, ROC, precision-recall (PR) Curve, and decision curve analyses. Feature importance was interpreted using Shapley additive explanations (SHAP) and visualized using decision tree. Results The PDOs-CAFs-T cells co-culture platform showed cytokine-change trends that were generally concordant with those observed in patient serum after treatment. 10 key predictors were identified, including pre-/post-treatment maximum diameter, ycT/ycN stages, and pre- or post-treatment cytokines (IFN-α2, IL-2, IL-6, IL-8, MCP-1). In the internal testing set, the tuned CatBoost model achieved an AUC of 0.845. SHAP analysis revealed post-treatment maximum diameter and cytokine profiles as the most influential features. Decision trees clearly and interpretably present the model. Conclusion This study presents an exploratory, biologically informed machine learning framework for peri-treatment assessment of pathological response in gastric cancer. The PDOs-CAFs-T cells co-culture platform provided biological context for candidate cytokine selection.
- 2 July 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (31) , 3258-3272
Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization
The tumor microenvironment is a critical regulator of cancer progression. Histone lactylation, a novel post-translational modification, has emerged as a key player in various tumors and is closely linked to macrophage polarization within the immune tumor microenvironment. Here, we delineated the signaling axis through which histone lactylation, specifically H3K18la, orchestrates crosstalk between intrahepatic cholangiocarcinoma cells and the tumor microenvironment (TME). Cleavage Under Target and Tagmentation analysis revealed an enrichment of H3K18la at the promoter of the N6-methyladenosine reader protein insulin-like growth factor-2 mRNA-binding protein 3 (IGF2BP3), enhancing its transcription. IGF2BP3 stabilizes the mRNA of the key factor secreted phosphoprotein 1 (SPP1), thereby promoting its secretion. Single-cell RNA sequencing indicated that tumor-derived SPP1 promoted intrahepatic cholangiocarcinoma (iCCA) progression by acting on macrophages via the SPP1/CD44 axis, inducing M2 polarization and migration to shape an immunosuppressive tumor microenvironment. Furthermore, using clinically relevant patient-derived organoids, xenograft models, and immunocompetent mouse models, we demonstrated that a glycolysis inhibitor synergizes with the first-line chemotherapeutic agent gemcitabine, significantly enhancing its therapeutic efficacy. These findings deliver a new exploration and important supplement of metabolic reprogramming, epigenetic regulation, and tumor immune microenvironment, and provide a new strategy for improving clinical efficacy of gemcitabine in iCCA by inhibiting histone lactylation.
- 2 July 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (31) , 3258-3272
Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization
The tumor microenvironment is a critical regulator of cancer progression. Histone lactylation, a novel post-translational modification, has emerged as a key player in various tumors and is closely linked to macrophage polarization within the immune tumor microenvironment. Here, we delineated the signaling axis through which histone lactylation, specifically H3K18la, orchestrates crosstalk between intrahepatic cholangiocarcinoma cells and the tumor microenvironment (TME). Cleavage Under Target and Tagmentation analysis revealed an enrichment of H3K18la at the promoter of the N6-methyladenosine reader protein insulin-like growth factor-2 mRNA-binding protein 3 (IGF2BP3), enhancing its transcription. IGF2BP3 stabilizes the mRNA of the key factor secreted phosphoprotein 1 (SPP1), thereby promoting its secretion. Single-cell RNA sequencing indicated that tumor-derived SPP1 promoted intrahepatic cholangiocarcinoma (iCCA) progression by acting on macrophages via the SPP1/CD44 axis, inducing M2 polarization and migration to shape an immunosuppressive tumor microenvironment. Furthermore, using clinically relevant patient-derived organoids, xenograft models, and immunocompetent mouse models, we demonstrated that a glycolysis inhibitor synergizes with the first-line chemotherapeutic agent gemcitabine, significantly enhancing its therapeutic efficacy. These findings deliver a new exploration and important supplement of metabolic reprogramming, epigenetic regulation, and tumor immune microenvironment, and provide a new strategy for improving clinical efficacy of gemcitabine in iCCA by inhibiting histone lactylation.